In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a price target of $59.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
William Plovanic has given his Buy rating due to a combination of factors that highlight Tandem Diabetes Care’s promising outlook. Key among these is the company’s robust product pipeline, which is expected to drive growth both in the near term and over the longer horizon. Additionally, the automation of customer service and other operational efficiencies are anticipated to enhance operating margins, providing a solid foundation for future profitability.
Another significant factor is the untapped potential in the Type 2 Diabetes (T2D) market, which represents a massive growth opportunity for Tandem. The company’s strategic initiatives, such as the transition in OUS distribution and recent changes in the sales force, are expected to further bolster revenue. With a favorable valuation and positive free cash flow, Tandem is well-positioned to capitalize on these opportunities, justifying the Buy rating and the $59 price target.
In another report released on May 2, Barclays also maintained a Buy rating on the stock with a $53.00 price target.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year.